Biotech Biz Evozyne Closes $81M Series B Funding Round
Chicago-based biotechnology company Evozyne on Wednesday revealed that it completed its Series B funding round after raising $81 million that will be used to help fund its generative artificial intelligence-powered drug...To view the full article, register now.
Already a subscriber? Click here to view full article